Literature DB >> 11021733

Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma.

J D Moore1, B J Dezube, P Gill, X J Zhou, E P Acosta, J P Sommadossi.   

Abstract

The pharmacokinetics of TNP-470 and its major metabolites were investigated in AIDS patients enrolled in a phase I dose escalation trial for the treatment of Kaposi's sarcoma. The patients received TNP-470 by 1-h intravenous infusion in dose cohorts of 10, 20, 30, 40, 50 and 70 mg/m2. The parent drug and metabolites, MII and MIV, were measured by high-performance liquid chromatography/mass spectrometry (HPLC/MS) in plasma samples collected during and out to 168 h after the beginning of the infusion. Both metabolites were detected in all patients' plasma, while the parent drug was undetectable at time-points as early as 5 min after the end of infusion for some patients. A large interpatient variability of pharmacokinetic parameters among the dosing cohorts was observed for TNP-470, with a mean (+/- SD) plasma elimination half-life (t1/2) of 0.06 +/- 0.04 h, plasma clearance (CL) of 1487 +/- 1216 l/h and an area under the concentration versus time curve (AUC) of 49.9 +/- 35.8 ng/ml x h. Time to maximum plasma concentration (Tmax) typically occurred before the end of the infusion. The predominant plasma metabolite was MII with a t1/2 of 1.21 +/- 0.43 h, AUC of 1226 +/- 2303 l/h and a Tmax occurring between 5 and 15 min after infusion. The reported active metabolite MIV had a t1/2 of 0.24 +/- 0.13 h, AUC of 24.9 +/- 32.6 ng/ml x h and a Tmax occurring between the midpoint of the infusion and 15 min after infusion. The parent drug was undetectable by HPLC/MS/MS in urine samples collected and pooled between 0-6 and 6-24 h from the beginning of drug administration. Metabolite MIV was present in the 0-6-h urine pool of two patients enrolled in the highest dosing cohorts, equivalent to 0.4% of the administered dose. Metabolite MII was present in all 0-6-h samples analyzed and represented 1.12 +/- 0.9% of the administered dose. Renal clearance (CLR) for MII was 140 +/- 70 ml/h.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11021733     DOI: 10.1007/s002800000149

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  4 in total

1.  Injection of antiangiogenic agents into the macaque preovulatory follicle: disruption of corpus luteum development and function.

Authors:  Timothy M Hazzard; Richard M Rohan; Theodore A Molskness; John W Fanton; Robert J D'Amato; Richard L Stouffer
Journal:  Endocrine       Date:  2002-04       Impact factor: 3.633

2.  Antimicrosporidial activities of fumagillin, TNP-470, ovalicin, and ovalicin derivatives in vitro and in vivo.

Authors:  Peter J Didier; Jennifer N Phillips; Dorothy J Kuebler; Mohamed Nasr; Paul J Brindley; Mary E Stovall; Lisa C Bowers; E S Didier
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Diagnosis and Treatment of Kaposi's Sarcoma.

Authors:  Muhammad Wasif Saif
Journal:  Resid Staff Physician       Date:  2001-11

4.  The potential of nanomedicine therapies to treat neovascular disease in the retina.

Authors:  Krysten M Farjo; Jian-Xing Ma
Journal:  J Angiogenes Res       Date:  2010-10-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.